Journal
FRONTIERS IN MEDICINE
Volume 4, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fmed.2017.00069
Keywords
celastrol; inflammation; cancer; neurodegenerative diseases; toxicity; treatment; clinical trials
Categories
Funding
- Fundacao para a Ciencia e a Tecnologia (FCT) [SFRH/BPD/92860/2013]
- European Research Council [ERC-2014-CoG647888-iPROTECTION]
- FCT [PTDC/BIM-MEC/4665/2014]
- Fundação para a Ciência e a Tecnologia [SFRH/BPD/92860/2013, PTDC/BIM-MEC/4665/2014] Funding Source: FCT
Ask authors/readers for more resources
The identification of new bioactive compounds derived from medicinal plants with significant therapeutic properties has attracted considerable interest in recent years. Such is the case of the Tripterygium wilfordii (TW), an herb used in Chinese medicine. Clinical trials performed so far using its root extracts have shown impressive therapeutic properties but also revealed substantial gastrointestinal side effects. The most promising bioactive compound obtained from TW is celastrol. During the last decade, an increasing number of studies were published highlighting the medicinal usefulness of celastrol in diverse clinical areas. Here we systematically review the mechanism of action and the therapeutic properties of celastrol in inflammatory diseases, namely, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel diseases, osteoarthritis and allergy, as well as in cancer, neurodegenerative disorders and other diseases, such as diabetes, obesity, atherosclerosis, and hearing loss. We will also focus in the toxicological profile and limitations of celastrol formulation, namely, solubility, bioavailability, and dosage issues that still limit its further clinical application and usefulness.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available